BioSpace News Archive

The Annual General Meeting in Oncopeptides AB was held on Wednesday, 26 May 2021. At the Annual General Meeting, the following principal resolutions were passed.

Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as chief operating officer

Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will participate at the following conferences

TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10 th at 5:00 PM ET – Company to report conclusions from its comprehensive strategic review, outline its updated business plan and report its fiscal year 2021 financial results

Dr. Stephen Palmer joins the Celmatix executive team to lead the company’s drug discovery and development efforts in ovarian health as Chief Scientific Officer

Verseau Therapeutics, Inc. today announced the appointment of John Edwards as Chief Executive Officer. John brings over 30 years of biopharmaceutical leadership experience and has been involved in the discovery, development or global commercialization of 10 FDA-approved biologics and eight biotech companies with successful exits.

Synexis today announced the appointment of Karin De Bondt to the Synexis board of directors, effective immediately.

Cortexyme, Inc., a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021

Tranquis Therapeutics, a private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced that it has strengthened its management team

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors.